Gilead Sciences | GILD - Stock


Gilead Sciences reported $1.91B in Stock for its fiscal quarter ending in March of 2026.





Stock Change Date
AbbVie USD 5.05B 98M Mar/2026
Agios Pharmaceuticals USD 35.09M 2.17M Mar/2026
ALKERMES USD 336.7M 140.08M Mar/2026
Alnylam Pharmaceuticals USD 200.15M 117.43M Mar/2026
Amgen USD 6.19B 39M Mar/2026
Biogen USD 1.95B 219.1M Mar/2026
BioMarin Pharmaceutical USD 1.27B 25.66M Mar/2026
Bristol-Myers Squibb USD 2.76B 66M Mar/2026
Coherus Biosciences USD 3.17M 1.12M Dec/2025
Eli Lilly USD 14.53B 785M Mar/2026
Gilead Sciences USD 1.91B 140M Mar/2026
GlaxoSmithKline GBP 6.16B 233M Mar/2026
Glaxosmithkline GBP 6.12B 46M Sep/2025
Incyte USD 115.62M 14.56M Mar/2026
J&J USD 14.58B 392M Mar/2026
Merck USD 6.48B 179M Mar/2026
Moderna USD 146M 7M Mar/2026
Neurocrine Biosciences USD 64.5M 4.5M Mar/2026
Novartis USD 6.29B 17M Mar/2026
Pfizer USD 10.67B 13M Mar/2026
PTC Therapeutics USD 75.57M 4.08M Mar/2026
Puma Biotechnology USD 9.48M 885K Sep/2025
Regeneron Pharmaceuticals USD 3.1B 97.2M Mar/2026
Sanofi EUR 22.69B 1.81B Dec/2025
Sarepta Therapeutics USD 1B 86.37M Mar/2026
United Therapeutics USD 178.3M 4.8M Mar/2026
Vertex Pharmaceuticals USD 1.77B 79.9M Mar/2026